博暉創新(300318.SZ):與內蒙古相關政府簽訂戰略合作協議 建年處理2000噸原料血漿生產基地
格隆匯 9 月 7日丨博暉創新(300318.SZ)公佈,2020年9月7日,公司與呼和浩特市人民政府、內蒙古和林格爾新區管理委員會共同簽署了《內蒙古和林格爾新區博暉創新生物技術產業基地項目合作框架協議》。
項目公司在內蒙古和林格爾新區規劃分期投資建設生物技術產業基地,主要有建設包括微流控檢測分析儀器、芯片、配套試劑在內的全套組合生產線;建設生物技術研發中心;建設年處理2000噸原料血漿生產基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.